Alongside previous data, the internalization of engineered Fn3 variants that bindMSLN suggests the inclusion of alpha-emitting radionuclides as moleculesof interest for future studies., The shedding of MSLNfrom the tumor cell surface appears to be a factor in reducing theefficacy of MSLN-targeting therapeutic approaches with antibody andCAR T-cell approaches in vivo. The gene discussed is MSLN; the disease is neoplasm.